Pfizer (NYSE:PFE) issued an update on its FY19 earnings guidance on Tuesday morning. The company provided EPS guidance of $2.82-2.92 for the period, compared to the Thomson Reuters consensus EPS estimate of $3.04. The company issued revenue guidance of $52-54 billion, compared to the consensus revenue estimate of $54.31 billion.Pfizer also updated its FY 2019 guidance to $2.82-2.92 EPS.
NYSE:PFE traded up $0.87 during trading hours on Thursday, reaching $42.45. The company’s stock had a trading volume of 38,505,206 shares, compared to its average volume of 26,304,212. The stock has a market capitalization of $242.70 billion, a PE ratio of 14.15, a P/E/G ratio of 2.10 and a beta of 0.87. Pfizer has a one year low of $33.20 and a one year high of $46.47. The company has a current ratio of 1.43, a quick ratio of 1.15 and a debt-to-equity ratio of 0.47.
Pfizer (NYSE:PFE) last issued its quarterly earnings data on Tuesday, January 29th. The biopharmaceutical company reported $0.64 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of $0.63 by $0.01. The firm had revenue of $13.98 billion during the quarter, compared to analysts’ expectations of $13.92 billion. Pfizer had a net margin of 20.79% and a return on equity of 25.38%. Pfizer’s revenue for the quarter was up 2.0% on a year-over-year basis. During the same period in the prior year, the company posted $0.62 earnings per share. On average, sell-side analysts forecast that Pfizer will post 2.88 earnings per share for the current fiscal year.
Pfizer declared that its Board of Directors has approved a share buyback plan on Friday, December 14th that authorizes the company to buyback $10.00 billion in shares. This buyback authorization authorizes the biopharmaceutical company to reacquire up to 3.8% of its shares through open market purchases. Shares buyback plans are typically a sign that the company’s board believes its shares are undervalued.
A number of research analysts have recently commented on PFE shares. Independent Research set a $48.00 price objective on shares of Pfizer and gave the company a neutral rating in a research report on Thursday, October 4th. Cantor Fitzgerald set a $45.00 price target on shares of Pfizer and gave the stock a buy rating in a research note on Thursday, October 4th. Morningstar set a $46.00 price target on shares of Pfizer and gave the stock a neutral rating in a research note on Tuesday, October 9th. ValuEngine raised shares of Pfizer from a hold rating to a buy rating in a research note on Tuesday, October 9th. Finally, Credit Suisse Group set a $40.00 price target on shares of Pfizer and gave the stock a hold rating in a research note on Sunday, October 14th. Three analysts have rated the stock with a sell rating, fourteen have assigned a hold rating and seven have assigned a buy rating to the company’s stock. The company currently has a consensus rating of Hold and a consensus target price of $44.24.
A hedge fund recently raised its stake in Pfizer stock. Morgan Stanley lifted its position in shares of Pfizer Inc. (NYSE:PFE) by 2.1% during the third quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 55,493,846 shares of the biopharmaceutical company’s stock after buying an additional 1,126,612 shares during the quarter. Pfizer makes up 0.6% of Morgan Stanley’s holdings, making the stock its 17th largest holding. Morgan Stanley owned about 0.93% of Pfizer worth $2,445,614,000 at the end of the most recent quarter. 69.16% of the stock is owned by hedge funds and other institutional investors.
Pfizer Inc discovers, develops, manufactures, and sells healthcare products worldwide. It operates in two segments, Pfizer Innovative Health (IH) and Pfizer Essential Health (EH). The IH segment focuses on the development and commercialization of medicines and vaccines, and consumer healthcare products in various therapeutic areas, including internal medicine, vaccines, oncology, inflammation and immunology, and rare diseases, as well as consumer healthcare, such as over-the-counter brands comprising dietary supplements, pain management, gastrointestinal, and respiratory and personal care.
Further Reading: LIBOR
Receive News & Ratings for Pfizer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer and related companies with MarketBeat.com's FREE daily email newsletter.